Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.
about
Recommended reading in population pharmacokinetic pharmacodynamicsPharmacokinetics of temafloxacin in humans after multiple oral dosesA drug-disease model describing the effect of oseltamivir neuraminidase inhibition on influenza virus progression.A Review of Modeling Approaches to Predict Drug Response in Clinical OncologyBasic Concepts in Population Modeling, Simulation, and Model-Based Drug DevelopmentNonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosisFitting a regression model for genotype-by-environment data on heading dates in grasses by methods for nonlinear mixed models.Estimation of half-life periods in nonlinear data with fractional polynomials.Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical dataModeling and simulation of count data.Mixed Effects Modeling Using Stochastic Differential Equations: Illustrated by Pharmacokinetic Data of Nicotinic Acid in Obese Zucker Rats.Analysis of population pharmacokinetic data using NONMEM and WinBUGS.An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics.Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients.Non-linear Models for Longitudinal Data.Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia.A novel Gibbs maximum a posteriori (GMAP) approach on Bayesian nonlinear mixed-effects population pharmacokinetics (PK) modelsSystems engineering medicine: engineering the inflammation response to infectious and traumatic challenges.Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.Drug dosage individualization based on a random-effects linear model.The pharmacokinetics and angiotensin converting enzyme inhibition dynamics of cilazapril in essential hypertension.Pulmonary disposition of pethidine in postoperative patients.Jejunal proteins secreted by db/db mice or insulin-resistant humans impair the insulin signaling and determine insulin resistanceA multiphase non-linear mixed effects model: An application to spirometry after lung transplantationInterpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjectsPharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study.Population pharmacokinetic modeling of the Qishe pill in three major traditional Chinese medicine-defined constitutional types of healthy Chinese subjects: study protocol for a randomized controlled trialReporting guidelines for population pharmacokinetic analyses.Self-modeling ordinal regression with time invariant covariates - An application to prostate cancer data.Prolonged Acetaminophen-Protein Adduct Elimination During Renal Failure, Lack of Adduct Removal by Hemodiafiltration, and Urinary Adduct Concentrations After Acetaminophen Overdose.Improved Estimation of Human Lipoprotein Kinetics with Mixed Effects ModelsFitting and Calibrating a Multilevel Mixed-Effects Stem Taper Model for Maritime Pine in NW Spain.Population pharmacokinetics I: background, concepts, and models.Population pharmacokinetics II: estimation methods.Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndromeShrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impactMechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patientsBayesian clinical trials in actionPopulation pharmacokinetics of phenytoin from routine clinical data in Japan.
P2860
Q24647906-6D2387D7-A92C-4DCB-9E57-28B973881294Q24679273-77257C29-003C-4E0B-AA2C-62A56AC9D7B8Q27324423-6B5F4023-0CD7-41AE-926C-7B2323386291Q28066777-4E718CE4-99BF-45F4-9717-F306C268CD78Q29013931-7E437C38-3E5F-4796-90E5-3C6D0EBFACABQ30489162-3859A805-1865-407A-8462-2E71319DBC87Q30649789-49FA94E7-F8BB-43DD-8B51-A07555DA9E34Q30664703-5AD62458-EE8E-40BC-B79F-5D97E07712CCQ30666721-EDDE9F2E-0685-439B-AE7D-894CEF931D63Q30842267-BAA31E79-5226-440F-9FBE-82A02F22C144Q30895231-DCD7B0C1-8328-4B23-A44A-364CE0EE3DA2Q30982415-5224B9C5-9171-495C-84E4-FA39A7683DB1Q31131623-E184DA2D-5F42-4752-BFAE-D5CFC6DF9E69Q33415594-282488C6-B17E-4092-AAB8-8FC83E0D3525Q33531670-8937A29C-9AEB-455A-ABEC-32E4D28D99F4Q33571417-2E1E9660-711E-407C-BD18-5ACC86C31B46Q33692989-3AD3FC41-6C56-4E56-A112-B4AAFC55250AQ33891519-3122B7F2-5B84-4EF7-B9E0-BC2FD561D819Q34113462-F8C3CB5B-6956-4BF7-BD74-52E2A2537C3FQ34261199-52DD4D2A-09FD-4355-B5EB-1491EC4D666CQ34397120-5C6BCA03-417A-415D-9A9B-05F0DDE1FAE7Q34417668-D7E3FBFA-8134-48AA-B2FE-DB0736FB6D3CQ34598510-9AA849E0-3250-43B9-AF6B-0F435227D48EQ34681751-D1EFF736-6E6B-488F-8AAE-61CBDCFE23C6Q34996894-77D75232-AC84-4CB4-B6A0-11FA5E0A55E4Q35135626-3AA65DE7-9319-4EBE-B7B0-78FF60A8EE34Q35135977-5A00A5F0-7E27-4879-A883-E458E81589BAQ35154416-02BCC32B-1290-45DD-AE47-FB75A50DF719Q35607607-1856B4C3-842C-44F2-BDB5-A341A192B151Q35721492-71C73AB8-FEFE-4ABE-B5BE-1811E996DB25Q35749131-39980969-824D-45D5-8289-71CBAC8ABC2EQ35793610-77F045C8-1A45-433E-A243-72541AF89B8FQ35858804-1412C8A8-64D2-4B76-8372-717BC578CE08Q35870696-E65BE7A4-01BD-4F58-8FAC-F15D3CC6C0A8Q35887615-DB626048-0F99-4B8D-81EC-411881FBB817Q35972218-CB655004-5F70-4E78-BC54-81034B1938E1Q36331482-D0F95835-C641-4A04-A42B-7D31C2817F0EQ36344679-593ED20E-E75F-403B-9302-848AFBC30CD8Q36392556-32A01335-43EF-4C12-8D3D-F45C5F93A889Q36417519-C61BBA7E-BC21-4D37-90B5-633011CB121F
P2860
Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.
description
1980 nî lūn-bûn
@nan
1980年の論文
@ja
1980年論文
@yue
1980年論文
@zh-hant
1980年論文
@zh-hk
1980年論文
@zh-mo
1980年論文
@zh-tw
1980年论文
@wuu
1980年论文
@zh
1980年论文
@zh-cn
name
Evaluation of methods for esti ...... clinical pharmacokinetic data.
@ast
Evaluation of methods for esti ...... clinical pharmacokinetic data.
@en
type
label
Evaluation of methods for esti ...... clinical pharmacokinetic data.
@ast
Evaluation of methods for esti ...... clinical pharmacokinetic data.
@en
prefLabel
Evaluation of methods for esti ...... clinical pharmacokinetic data.
@ast
Evaluation of methods for esti ...... clinical pharmacokinetic data.
@en
P356
P1476
Evaluation of methods for esti ...... clinical pharmacokinetic data.
@en
P2093
P2888
P304
P356
10.1007/BF01060053
P577
1980-12-01T00:00:00Z